期刊文献+

榄香烯联合三苯氧胺对乳腺癌MCF-7细胞株的抑制效应 被引量:10

The inhibitory effect of elemene combined with tamoxifen on the breast cancer MCF-7 cell line
暂未订购
导出
摘要 目的观察榄香烯和三苯氧胺对乳腺癌细胞的抑制效应,尤其是两者联合应用有无协同增效作用。方法将MCF-7细胞培养于RPMI1640培养基中,置入37℃,100%湿度,5%(体积分数)的CO2培养箱内。接种细胞并加入实验药物,用CCK-8法检测三苯氧胺联合榄香烯对细胞的增殖抑制效应,用酶标仪在450nm测量每孔吸光度值,计算每组细胞抑制率。结果无毒剂量的榄香烯与治疗剂量的三苯氧胺联合应用,吸光度均值较单用三苯氧胺明显下降,并且相应的细胞抑制效应较单用组明显上升。结论无毒剂量的榄香烯能够使三苯氧胺对乳腺癌细胞的抑制效应显著增强,提示榄香烯与三苯氧胺联合应用具有协同作用。 Objective To explore if clement can syncrgize tamoxifen through using non-cytotoxic dose of clement and tamoxifen in combination on MCF-7cell line of breast cancer. Methods First, MCF-7 cell line was cultured in RPMI1640. Then, TAM's inhibitory effect united with clement on MCF-7 cell line was analyzed by using CCK-8 test. Results When adding non-cytotoxic dose of clement and curative dose of tamoxifen into the two experimental groups, the absorptivity in the two groups reduced notably, compared with that of the groups using tamoxifen alone; accordingly, the inhibition rate in two mixing groups increased obviously compared with that in single-drug groups. Conclusion Element of innocuous dose can remarkably enhance the inhibitory effect of tamoxifen, which indicates that clement may synergize the effect of tamoxifen on breast cancer.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2007年第1期74-77,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 陕西省自然科学基金资助项目(No.20021210-G3(05))
关键词 乳腺癌 三苯氧胺 榄香烯 协同作用 breast cancer tamoxifen elemene synergistic effect
  • 相关文献

参考文献8

二级参考文献49

  • 1Howell A, Osborne CK, Morris C,et al. ICI 182,780 (Faslodex) :development of a novel, "pure" antiestrogen. Cancer, 2000, 89(4) :817 - 825.
  • 2Nabholtz JM, Bozdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first - line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 2000, 18(22) : 3758 - 3767.
  • 3Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first - line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 2000,18 (2) :3748 - 3757.
  • 4Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first - line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol,2001, 19(i0) : 2596 - 2606.
  • 5Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer, 1998 ,83(6) :1142 - 1152.
  • 6Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double - blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol, 1998,16 (2) :453 - 461.
  • 7Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tarnoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double - blind trial. The Exemestane Study Group. J Clin Oncol, 2000, 18(7):1399- 1411.
  • 8Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily,0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group(AR/BC3). Ann Oncol, 1998, 9(3): 639-645.
  • 9Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibiters: a phase Ⅱ trial. J Clin Oncol, 2000, 18(11): 2234-2244.
  • 10Howell A, Robertson JF, Quaresma AJ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol,2002,20(16):3396 -3403.

共引文献66

同被引文献109

引证文献10

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部